Ranibizumab Application Scope

Ranibizumab is an anti-VEGF (vascular endothelial growth factor A) monoclonal antibody fragment used to treat ocular diseases caused by abnormal angiogenesis and vascular leakage.
It is mainly indicated for neovascular (wet) age-related macular degeneration (AMD), diabetic macular edema (DME), diabetic retinopathy (DR), macular edema following retinal vein occlusion (RVO), and myopic choroidal neovascularization (mCNV).

Ranibizumab Characteristics

Ingredients: Ranibizumab (Fab fragment of humanized monoclonal antibody against VEGF-A).
Properties: Sterile, clear, colorless to slightly yellow aqueous solution for intravitreal injection.
Packaging Specification: Prefilled syringes: 10mg × 1 syringe/box; single-use vials also available.
Storage: Store at 2–8 °C, protect from light, do not freeze.
Expiry Date: As indicated on the carton; shelf life typically 12–24 months.
Executive Standard: Ophthalmic biological product standard (refer to local NMPA / FDA / EMA).
Approval Number: As shown on local approval document.
Date of Revision: As printed on package insert.
Manufacturer: Novartis / Genentech (region dependent).

Guidelines for the Use of Lucentis

Dosage and Administration:
- Administration: For intravitreal use only, under aseptic conditions by trained ophthalmologists.
- Missed Dose: Administer as soon as possible, then continue regular schedule.
Adverse Reactions:
- Common Adverse Reactions:
  - Conjunctival hemorrhage
  - Eye pain or irritation
  - Increased intraocular pressure
  - Vitreous floaters
  - Mild ocular inflammation
  - Transient blurred vision
- Serious Adverse Reactions:
  - Endophthalmitis
  - Retinal detachment
  - Severe intraocular inflammation
  - Vitreous hemorrhage
  - Rare arterial thromboembolic events (stroke, myocardial infarction)
Contraindications:
- Active ocular or periocular infection
- Hypersensitivity to ranibizumab or its excipients
Precautions:
- Maintain aseptic injection technique to minimize infection risk.
- Monitor intraocular pressure immediately after injection.
- Use caution in patients with recent arterial thromboembolic events.
- Use during pregnancy or lactation only if potential benefit outweighs risk.
- Do not mix with other drugs in the same syringe or vial.

Ranibizumab Interactions

No clinically significant systemic drug interactions reported.
Concurrent ocular procedures may increase inflammation or infection risk — manage with caution.

Note:

If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from DengYue Medicine.
This content is for reference only. Prescription drugs must be used under a doctor’s guidance and purchased from authorized sources.